Evaluation of dexamethasone effects in COVID-19 treatment

Abstract

(COVID-19) Finding a cure for Corona virus sickness in 2019 will be a difficult task for researchers all over the globe, since it is associated with significant lung damage and the potential for multiple organ failure. To far, dexamethasone has shown substantial benefits in COVID-19, reducing mortality while improving recovery. There is a reduction in inflammation due to a reduction in inflammation-related immune responses and a decrease in cytokine production, which prevents COVID-19 from becoming more severe. Dexamethasone's significance in the treatment of COVID-19 is currently unproven. When it comes to combating this pandemic, COVID-19's pathophysiology and dexamethasone's efficacy are the deciding factors.

C-reactive protein in patients with COVID-19

“…In COVID-19 patients, elevated CRP levels signal the necessity for mechanical ventilation. Elevated CRP levels associated with elevated IL-6 release significantly predict the need for respiratory support [33,44,47], implying that CRP could be used to guide therapy in COVID-19 patients who may require mechanical ventilation in the future due to hyper-inflammatory disease [48,49,50],. To avoid negative results in COVID-19 patients, CRP must be controlled.…”